Trial Profile
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Asvasiran sodium (Primary)
- Indications Bronchiolitis obliterans; Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 03 Sep 2015 Results published in the Journal of Heart and Lung Transplantation
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.